on CROSSJECT (EPA:ALCJ)
Crossject announces a fundraising of 7 million euros
Crossject, a specialty pharmaceutical company, announces a €7 million private placement. The transaction includes a capital increase and the issuance of warrants reserved for qualified investors. Maxim Group LLC and Invest Securities are acting as lead agents. The funds will support the development of ZEPIZURE®, a needle-free auto-injector, prior to an application for FDA approval.
More than half of the funds will be allocated to the development of ZEPIZURE®, with the remainder supporting R&D and other projects. The funding will enable Crossject to cover its needs until mid-2025. Shareholder Gemmes Venture, together with Heights Capital Management, will make a significant contribution to this transaction.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news